RT Journal Article
T1 Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.
A1 Ángel Calleja, Miguel
A1 Navarro, Andrés
A1 Serratosa, José María
A1 Toledo, Manuel
A1 Villanueva, Vicente
A1 Subías Labazuy, Silvia
A1 Gil, Alicia
K1 Anti-seizure medications
K1 Spain
K1 cenobamate
K1 cost-effectiveness
K1 drug-resistant epilepsy
K1 economically justifiable price
AB To determine the economically justifiable price (EJP) of cenobamate to become a cost-effective alternative compared with third-generation anti-seizure medications in the treatment of focal-onset seizures (FOS) in adult patients with drug-resistant epilepsy (DRE) in Spain. Cost-effectiveness analysis compared cenobamate with brivaracetam, perampanel, eslicarbazepine acetate, and lacosamide. Markov model simulation of treatment pathway over a 60-year time horizon is presented. We determined the effectiveness and quality-adjusted life-years (QALYs) of health status and disutilities associated with treatment-related adverse events. Acquisition costs and use of medical resources were obtained from published literature and expert opinion. Base-case of cenobamate's EJP calculated applying a willingness-to-pay (WTP) threshold of €21,000/QALY. Analyses were performed at different thresholds, including dominant price scenario. Result robustness was assessed through sensitivity analyses. Base-case shows that cenobamate's daily EJP of €7.30 is cost-effective for a threshold of €21,000/QALY. At a daily price of €5.45, cenobamate becomes dominant over all treatment alternatives producing cost-savings for the national health system (NHS). Sensitivity analyses supported the robustness of base-case findings. Treatment with cenobamate produces incremental clinical benefit over third-generation ASMs, and at the base-case, EJP could represent a cost-effective option for the adjunctive treatment of FOS in adult patients with DRE in Spain.
YR 2022
FD 2022-08-03
LK http://hdl.handle.net/10668/19682
UL http://hdl.handle.net/10668/19682
LA en
DS RISalud
RD Jul 5, 2025